# Quoin Pharmaceuticals, Ltd. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Quoin Pharmaceuticals, Ltd.). ## Overview Quoin Pharmaceuticals, Ltd. is a U.S.-based specialty pharmaceutical company focused on developing proprietary therapies for rare and orphan diseases. Its lead program, QRX003, is a topical lotion based on a broad-spectrum serine protease inhibitor and the company’s proprietary Invisicare® technology, with development and planned commercialization activities spanning the United States and selected international markets. ## Products & services • QRX003 topical lotion for Netherton Syndrome • Rare-disease drug development programs • Proprietary Invisicare® formulation technology • Clinical, regulatory, and commercialization activities • Out-licensing and partnering opportunities - **Lead therapeutic candidate** (100%) — QRX003 and related clinical development work for rare dermatology indications. - **Drug delivery technology** (0%) — Proprietary Invisicare® formulation platform used to support topical product performance. - **Development-stage pipeline** (0%) — Additional rare-disease product candidates and in-licensed programs under evaluation. - QRX003 topical lotion for Netherton Syndrome - Rare-disease drug development programs - Proprietary Invisicare® formulation technology - Clinical, regulatory, and commercialization activities - Out-licensing and partnering opportunities ## Customers Quoin does not yet sell commercial products, so its near-term “customers” are primarily regulators, clinical investigators, and potential licensing or distribution partners rather than end-market patients. If approved, its therapies would be used by physicians and patients in rare-disease settings, with commercialization expected through direct sales in major markets and partners in other territories. - **Regulatory agencies** (primary) — FDA, EMA, and other authorities that review clinical data and marketing applications for QRX003. - **Clinical trial sites and investigators** (primary) — Hospitals and specialists that enroll and treat patients in late-stage studies of QRX003. - **Commercial partners** (secondary) — Distribution, licensing, and regional commercialization partners in non-core territories. - **Rare-disease physicians and patients** (primary) — Specialists and patients who would use approved therapies for Netherton Syndrome and similar orphan indications. - Regulators reviewing clinical and marketing applications - Clinical investigators running rare-disease trials - Potential distributors and commercialization partners - Physicians treating Netherton Syndrome and other rare diseases - Patients and caregivers in orphan-disease markets ## Geography Quoin is headquartered in the United States and is building a commercialization plan that includes the U.S., Europe, and Japan. It also references distribution partnerships across Canada, Australia/New Zealand, the Middle East, China, Hong Kong, Taiwan, Latin America, Central and Eastern Europe, Turkey, and Singapore, reflecting a geographically fragmented rare-disease market. - Headquartered in the United States - Planned commercialization in the U.S., Europe, and Japan - Partner-led distribution in Canada and Australia/New Zealand - Additional territories include the Middle East and Asia - Rare-disease markets are fragmented and require local access ## Strategy The company’s strategy centers on completing late-stage development of QRX003, securing marketing approvals, and preparing for commercialization in key markets. It also seeks to expand its pipeline through partnering, licensing, and acquisition opportunities, which is important for a small development-stage company with a narrow lead asset base. - **Complete clinical development of QRX003** (short-term) — Approval depends on successful late-stage data in Netherton Syndrome. - **Prepare commercialization infrastructure** (medium-term) — Approved orphan drugs require specialized sales and distribution capabilities. - **Broaden the pipeline** (medium-term) — A single-asset profile increases concentration risk and limits long-term optionality. - Advance QRX003 through late-stage clinical testing - Pursue marketing approvals in major global markets - Build direct sales capability in core territories - Use partners for regional distribution outside core markets - Expand pipeline through licensing and M&A ## Risks Quoin is exposed to the typical risks of a development-stage pharmaceutical company: clinical failure, regulatory delays, and the need for substantial external funding before product sales begin. Its small scale and Nasdaq listing dependence add financing and market-liquidity risk, while rare-disease commercialization also depends on reimbursement, physician adoption, and execution across multiple geographies. - **Clinical development failure for QRX003** [critical] — The company’s value depends heavily on late-stage success in Netherton Syndrome. - **Regulatory delay or rejection** [high] — Marketing approval is required before product sales can begin. - **Financing and dilution risk** [critical] — The company expects to fund operations through external capital until commercialization. - **Nasdaq delisting risk** [high] — Failure to meet continued listing standards could reduce liquidity and investor access. - **Commercial execution risk** [medium] — Rare-disease launches require specialized sales, distribution, and reimbursement access. - Clinical trials may fail or produce insufficient efficacy/safety data - Regulatory approval is uncertain and can require extra studies - Additional financing may be unavailable or highly dilutive - Nasdaq listing compliance risk could affect trading liquidity - Commercialization depends on partner execution in many regions ## Accounting As a development-stage biotech, Quoin’s reported results are driven mainly by research and development expense, stock-based compensation, and financing-related items rather than product revenue. Investors should watch the timing of clinical spending, fair-value accounting for marketable securities, and going-concern disclosures, since these can materially affect reported losses and liquidity presentation. - **Research and development expense timing** — Quarterly operating losses can swing with trial activity - **Stock-based compensation** — Affects operating expenses and comparability across periods - **Fair value of investments** — Impacts other income and reported net loss - **Going-concern disclosure** — Important for liquidity assessment and financing assumptions - R&D is expensed as incurred, so trial timing drives quarterly volatility - Stock-based compensation affects operating expense and loss trends - Marketable securities create interest income and fair-value changes - No product revenue yet, so commercialization timing is critical - Going-concern assessment reflects cash runway and financing assumptions --- *Last updated: 2026-04-29T04:50:57.076990+00:00*